About 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 (PFKFB1) is a protein
from Homo sapiens identified by UniProt accession
P16118, 471 residues long.
MolForge cross-references it against 0 known binders and
24 disease associations.
Target properties
| Protein name | 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 |
| UniProt accession | P16118 |
| Gene | PFKFB1 |
| Organism | Homo sapiens |
| Length | 471 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (24)
Diseases linked to this target (Open Targets).
- endometrial cancer · score 0.22
- Miyoshi myopathy · score 0.07
- hepatocellular carcinoma · score 0.02
- colorectal cancer · score 0.02
- cancer · score 0.02
- Neoplasm of the lung · score 0.01
- breast cancer · score 0.01
- Acute hepatic failure · score 0.01
- neoplasm · score 0.01
- COVID-19 · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P16118-F1 | alphafold | PREDICTED | 91.89 | — |
Amino-acid sequence (471 residues)
MSPEMGELTQ TRLQKIWIPH SSGSSRLQRR RGSSIPQFTN SPTMVIMVGL PARGKTYIST KLTRYLNWIG TPTKVFNLGQ YRREAVSYKN YEFFLPDNME ALQIRKQCAL AALKDVHNYL SHEEGHVAVF DATNTTRERR SLILQFAKEH GYKVFFIESI CNDPGIIAEN IRQVKLGSPD YIDCDREKVL EDFLKRIECY EVNYQPLDEE LDSHLSYIKI FDVGTRYMVN RVQDHIQSRT VYYLMNIHVT PRSIYLCRHG ESELNIRGRI GGDSGLSVRG KQYAYALANF IQSQGISSLK VWTSHMKRTI QTAEALGVPY EQWKALNEID AGVCEEMTYE EIQEHYPEEF ALRDQDKYRY RYPKGESYED LVQRLEPVIM ELERQENVLV ICHQAVMRCL LAYFLDKSSD ELPYLKCPLH TVLKLTPVAY GCKVESIYLN VEAVNTHREK PENVDITREP EEALDTVPAH Y
Explore 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets